Brown J Mark, Yu Liqing
Department of Pathology-Section on Lipid Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Immunol Endocr Metab Agents Med Chem. 2009 Mar;9(1):18-29. doi: 10.2174/187152209788009797.
Cholesterol is essential for the growth and function of all mammalian cells, but abnormally elevated levels of circulating low-density lipoprotein cholesterol (LDL-C) are a major risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). For many years, statin drugs have been used to effectively lower LDL-C, but ASCVD still persists in most of the world. Hence, additional LDL-C lowering is now recommended, and the search for therapeutic strategies that work in synergy with statins has now begun. Intestinal absorption and biliary excretion of cholesterol represent two major pathways and continue to show promise as druggable processes. Importantly, both of these complex physiological pathways are tightly regulated by key proteins located at the apical surface of the small intestine and the liver. One of these proteins, the target of ezetimibe Niemann-Pick C1-Like 1 (NPC1L1), was recently identified to be essential for intestinal cholesterol absorption and protect against excessive biliary sterol loss. In direct opposition of NPC1L1, the heterodimer of ATP-binding cassette transporters G5 and G8 (ABCG5/ABCG8) has been shown to be critical for promoting biliary cholesterol secretion in the liver, and has also been proposed to play a direct role in intestinal disposal of sterols. The purpose of this review is to summarize the current state of knowledge regarding the function of these opposing apical cholesterol transporters, and provide a framework for future studies examining these proteins.
胆固醇对于所有哺乳动物细胞的生长和功能至关重要,但循环中的低密度脂蛋白胆固醇(LDL-C)水平异常升高是动脉粥样硬化性心血管疾病(ASCVD)发生的主要危险因素。多年来,他汀类药物一直用于有效降低LDL-C,但在世界上大多数地区,ASCVD仍然存在。因此,现在建议进一步降低LDL-C,并且已经开始寻找与他汀类药物协同作用的治疗策略。胆固醇的肠道吸收和胆汁排泄是两个主要途径,作为可药物作用的过程仍然具有前景。重要的是,这两个复杂的生理途径都受到位于小肠和肝脏顶端表面的关键蛋白质的严格调控。其中一种蛋白质,依泽替米贝的靶点尼曼-匹克C1样1蛋白(NPC1L1),最近被确定为肠道胆固醇吸收所必需,并可防止胆汁中过多的固醇流失。与NPC1L1直接相反,ATP结合盒转运蛋白G5和G8(ABCG5/ABCG8)的异二聚体已被证明对促进肝脏中胆汁胆固醇分泌至关重要,并且也被认为在肠道固醇处理中起直接作用。本综述的目的是总结关于这些相反的顶端胆固醇转运蛋白功能的当前知识状态,并为未来研究这些蛋白质提供一个框架。